Format

Send to

Choose Destination
J Clin Invest. 2011 Aug;121(8):3005-23. doi: 10.1172/JCI46358. Epub 2011 Jul 11.

Perlecan domain V is neuroprotective and proangiogenic following ischemic stroke in rodents.

Author information

1
Department of Molecular and Cellular Medicine, Texas A&M College of Medicine, College Station, Texas 77843, USA.

Erratum in

  • J Clin Invest. 2012 Feb 1;122(2):777.

Abstract

Stroke is the leading cause of long-term disability and the third leading cause of death in the United States. While most research thus far has focused on acute stroke treatment and neuroprotection, the exploitation of endogenous brain self-repair mechanisms may also yield therapeutic strategies. Here, we describe a distinct type of stroke treatment, the naturally occurring extracellular matrix fragment of perlecan, domain V, which we found had neuroprotective properties and enhanced post-stroke angiogenesis, a key component of brain repair, in rodent models of stroke. In both rat and mouse models, Western blot analysis revealed elevated levels of perlecan domain V. When systemically administered 24 hours after stroke, domain V was well tolerated, reached infarct and peri-infarct brain vasculature, and restored stroke-affected motor function to baseline pre-stroke levels in these multiple stroke models in both mice and rats. Post-stroke domain V administration increased VEGF levels via a mechanism involving brain endothelial cell α5β1 integrin, and the subsequent neuroprotective and angiogenic actions of domain V were in turn mediated via VEGFR. These results suggest that perlecan domain V represents a promising approach for stroke treatment.

PMID:
21747167
PMCID:
PMC3148740
DOI:
10.1172/JCI46358
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for American Society for Clinical Investigation Icon for PubMed Central
Loading ...
Support Center